TNF and melanoma: Clinical trials of isolated limb perfusion (ILP) with recombinant human TNF-α and melphalan resulted in high complete response rates of 75–90% in patients with in-transit melanoma and unresectable sarcoma of the extremities (Lienard et al, 1992; Eggermont et al, 1996a,1996b).